$46.22
-0.93-1.97%
Last update: Nov 12, 7:34 PM
Arrowhead Pharmaceuticals Inc
ARWRNASDAQ
Arrowhead Pharmaceuticals rose 14.6% from $41.14 to $47.15, ahead of the S&P 500's +12.7%. Its worst day was Nov 9 (−15.3%), and its low came Nov 20 at $38.09.
Nov 13, 2025 – Nov 12, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.18 missed the $-0.05 estimate on $256.5M revenue (est. $175.5M).
+23.3% · S&P 500 +0.7%
Story events cover the past 12 months · Times ET
- ARO-MAPT utilizes the Targeted RNAi Molecule (TRiM™) platform designed for subcutaneous administration and systemic delivery to the CNS by crossing the blood-brain-barrier- Study initiation further highlights
+11.7% · S&P 500 −0.3%
ARO-INHBE in combination with tirzepatide achieved -9.4% weight loss at week 16 in obese patients with type 2 diabetes mellitus, demonstrating an approximately two-fold improvement versus -4.8% on tirzepatide
+10.8% · S&P 500 +0.6%
EPS of $0.22 beat the $0.02 estimate on $264.0M revenue (est. $256.6M).
−0.2%, on 24M shares, the year's heaviest volume · S&P 500 +1.9%
EPS of $-0.93 beat the $-1.14 estimate on $73.7M revenue (est. $69.3M).
−6.7% · S&P 500 +0.8%
Statistically significant reduction in acute pancreatitis events versus placebo across the entire sHTG study population, with an unprecedented 100% event reduction in high-risk patientsContinued and consistent safety
+19.0% · S&P 500 −0.1%
EPS of $-1.36 missed the $-1.19 estimate on $75.3M revenue (est. $51.2M).
−3.0% · S&P 500 −0.2%
Arrowhead Pharmaceuticals shares fell 12.4%, while the S&P 500 fell 0.5%.
−12.4% · S&P 500 −0.5%
Pooled SHASTA-3 and SHASTA-4 analysis showed plozasiran reduced acute pancreatitis event rates by 78% overall and 91% in sHTG patients with a recent history of acute pancreatitis versus placeboPALISADE open-label
−15.3%, the year's worst day · S&P 500 +2.4%
Where it ended: a close of $47.15 on Nov 12, 2026. Up next: Q1 2027 earnings on Feb 4, 2027 (EPS est. $-1.34, revenue est. $49.1M).
Nothing in the past 12 months.
All ARWR dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for ARWR and SPY from Benzinga historical bars. Not investment advice.
